This study showed that under the comprehensive treatment of CRC, receiving targeted therapy predicted better OS in patients who harbored TP53 GOF / known LOF mutations, but not in patients with TP53 non‐GOF / likely LOF mutations, providing evidence for the application of future personalized and precision medicine in the management of CRC patients. Here, TP53 is linked to colorectal carcinoma.